Claims

1 Use of a methylthioninium ("MT")-containing compound in the manufacture of a medicament for use in a method of therapeutic or prophylactic treatment of mild cognitive impairment in a human subject,

wherein the MT-containing compound is to be administered orally to the subject,

wherein a total daily dose of between 0.5 and 20mg of MT is to be administered to the subject per day, optionally split into 2 or more doses,

wherein the compound is LMTM:



.

2 Use as claimed in claim 1 wherein the total daily dosage is 2 to 15 mg; or 3 to 10 mg.

3 Use as claimed in claim 1 wherein the total daily dose is about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20mg.

4 Use as claimed in any one of claims 1 to 3 wherein the medicament is to be administered as a split dose twice a day or three times a day.

5 Use as claimed in any one of claims 1 to 4 wherein the total daily dose of LMTM is 0.8 to 33 mg/day, more preferably 6 to 12 mg/day of LMTM total.

6. Use as claimed in any one of claims 1 to 5 wherein the subject has not historically received treatment with an acetylcholinesterase inhibitor or an N-methyl-D-aspartate receptor antagonist.

7. Use as claimed in any one of claims 1 to 5 wherein the subject has historically received treatment with an acetylcholinesterase inhibitor and\or an N-methyl-D-aspartate receptor antagonist, but ceased that medication at least 1, 2, 3, 4, 5, 6, 7, or 8 weeks prior to treatment with the MT containing compound.

8. Use as claimed in any one of claims 1 to 5 wherein the subject is selected as one who is receiving treatment with an acetylcholinesterase inhibitor and\or an N-methyl-D-aspartate receptor antagonist,

wherein said treatment with the acetylcholinesterase inhibitor and\or an N-methyl-D-aspartate receptor antagonist is discontinued prior to treatment with the MT containing compound.